TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

International Journal of Medical Sciences

Volumn 5, Issue 2, 2008, Pages 87-91

  Palmblad, Jan ^a   Björkholm, Magnus ^a   Kutti, Jack ^b   Lärfars, Gerd ^c   Löfvenberg, Eva ^a   Markevärn, Berit ^d   Merup, Mats ^a   Mauritzson, Nils ^e   Westin, Jan ^e   Samuelsson, Jan ^c   Birgegård, Gunnar ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anagrelide; IL 6; Soluble receptors; Thrombocythemia; Thrombopoietin

Indexed keywords

ANAGRELIDE; INTERLEUKIN 6 RECEPTOR; THROMBOPOIETIN; ANTITHROMBOCYTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; MYELOFIBROSIS; POLYCYTHEMIA VERA; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; REMISSION; SAMPLE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPOIESIS; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; MIDDLE AGED; THROMBOCYTOSIS; TREATMENT OUTCOME;

ADULT; AGED; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; QUINAZOLINES; RECEPTORS, INTERLEUKIN-6; THROMBOCYTOSIS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 44449147183     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.87     Document Type: Article

References (34)

1. Anagrelide study group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-78.
2. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-6.
3. Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004;89:520-7.
4. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
5. Mazur EM, Rosmarin AG, Sohl PA et al. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-7.
6. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythemia treated with anagrelide. Br J Haematol 1999;104:886-892
7. Tomer A. Effects of anagrelide on invivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002; 99: 1602-9.
8. Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 2006;20:1117-22.
9. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339-47
10. McCarty JM, Melone PD, Simanis JP, Kanamori D, Dessypris EN, Warshamana-Greene S. A preliminary investigation into the action of anagrelide: Thrombopoietin-c-Mpl receptor interactions. Exp Haematology 2006;34:87-96.
11. Hou M, Carneskog J, Mellqvist UH, Stockelberg D, Hedberg M, Wadenvik H, Kutti J. Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis. Eur J Haematol 1998;61:119-22.
12. Griesshammer M, Hornkohl A, Nichol JL, Hecht T, Raghavachar A, Heimpel H, Schrezenmeier H. High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production? Ann Hematol 1998;77:211-5.
13. Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997;99:281-4.
14. Hsu HC, Tsai WH, Jiang ML, Ho CH, Hsu ML, Ho CK, Wang SY. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med 1999;134:392-7.
15. Griesshammer M, Kubanek B, Beneke H, Heimpel H, Bangerter M, Bergmann L, Schrezenmeier H. Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia. Leuk Lymphoma 2000;36:533-8
16. Tomita N, Motomura S, Sakai R, Fujimaki K, Tanabe J, Fukawa H, Harano H, Kanamori H, Ogawa K, Mohri H, Maruta A, Kodama F, Ishigatsubo Y, Tahara T, Kato T. Strong inverse correlation between serum TPO level and platelet count in essential thrombocythemia. Am J Hematol 2000;63:131-5.
17. Andreasson B, Lindstedt G, Stockelberg D, Wadenvik H, Kutti J. The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia. Leuk Lymphoma. 2001;41:579-84
18. Karakus S, Ozcebe OI, Haznedaroglu IC, Goker H, Ozatli D, Kosar A, BuyukasIk Y, Ertugrul D, SayInalp N, KirazlI S, Dundar SV. Circulating thrombopoietin in clonal versus reactive thrombocytosis. Hematology 2002;7:9-12.
19. Werynska B, Ramlau R, Podolak-Dawidziak M, Jankowska R, Prajs I, Usnarska-Zubkiewicz L, Kuliczkowski K. Serum thrombopoietin levels in patients with reactive thrombocytosis due to lung cancer and in patients with essential thrombocythemia. Neoplasma 2003;50:447-51.
20. Akiyama T, Matsunaga T, Terui T, Miyanishi K, Tanaka I, Sato T, Kuroda H, Takimoto R, Takayama T, Kato J, Yamauchi N, Kogawa K, Sakamaki S, Hirayama Y, Kohda K, Niitsu Y. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. Leukemia 2005;19:1558-66
21. Hirayama Y, Sakamaki S, Matsunaga T, Kuga T, Kuroda H, Kusakabe T, Sasaki K, Fujikawa K, Kato J, Kogawa K, Koyama R, Niitsu Y. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood 1998;92:46-52.
22. Uppenkamp M, Makarova E, Petrasch S, Brittinger G. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol 1998;77:217-23.
23. Espanol I, Hernandez A, Cortes M, Mateo J, Pujol-Moix N. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels. Haematologica 1999;84:312-6.
24. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, Bourantas KL. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130:709-15
25. Randi ML, Putti MC, Pacquola E, Luzzatto G, Zanesco L, Fabris F. Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia. Pediatr Blood Cancer 2005;44:47-50
26. Elliott MA, Yoon SY, Kao P, Li CY, Tefferi A. Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-mlp with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia. Eur J Haematol 2002;68:175-9.
27. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, McNiece IK.. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996;88:402-9.
28. Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A, Shide K, Matsuda T, Oshima K, Harada M. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res 2005;29:761-9.
29. Vannucchi AM, Bianchi L, Paoletti F, Pancrazzi A, Torre E, Nishikawa M, Zingariello M, Di Baldassarre A, Rana RA, Lorenzini R, Alfani E, Migliaccio G, Migliaccio AR. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.Blood 2005 ;105:3493-501
30. Marta R, Goette N, Lev P, Heller P, Kornblihtt L, Vassallu P, Glembotsky A, Pirola C, Molinas F. Increased levels of plasma interleukin-6 soluble receptor in patients with essential thrombocythemia. Haematologica 2004;89:657-63
31. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002;100:3495-503
32. Erusalimsky JD, Franklin R and Hong Y. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4- dihydroquinazoline (RL603)? Exp Haematol 2002;30:625-6
33. Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Huntly BJ, Nacheva EP, Barbui T, Finazzi G. A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. Hematology Am Soc Hematol Educ Program. 2000;:51-68.
34. Kutti J, Wadenvik H. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 1996;22:41-3.